Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...

What's the most attractive weight-loss stock right now? We asked Seeking Alpha analysts Edmund Ingham, Stephen Ayers and Oneil Trader for their picks. Read more here.

As many as 17% of men and 34% of women in the United States suffer from sleep apnea, and the numbers are increasing. KYW ...

If you've been scrolling through TikTok recently, you might have come across the "winter arc" trend — a sort of fresh take on ...

Shares of Allurion (NYSE:ALUR) soared 70% in post-market trading Thursday after ending the regular session 21% higher on news the company plans to conduct a clinical study of its gastric balloon ...

PEOPLE TAKING GLP-1S have a reduced risk of heart attacks, strokes, and death from cardiovascular disease, according to a ...

The injected Zepbound® produced a total of 38 adverse events across the study group of 9 persons, whereas the oral DehydraTECH-tirzepatide only produced 20 adverse events, a reduction of 47%.

Tirzepatide works by targeting multiple pathways ... not interfere with the active ingredients while providing necessary structure and consistency to the product. By maintaining a clean label ...

Mounjaro is the brand name for tirzepatide, and research shows that people with overweight and obesity have lost up to 25% of their body weight on this medication. Social media users have latched onto ...

Although tirzepatide use was associated with elevated amylase and lipase levels, risk for pancreatitis was not elevated among users of tirzepatide vs placebo. Tirzepatide does not yield a significant ...

The company attributed the revision to lower-than-expected sales of tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for obesity. “It’s always disappointing to miss your own ...